CD8A and cancer: SR717, a non‐nucleotide, small‐molecule STING agonist overcoming the limitation of metabolic instability of the natural cyclic dinucleotide (CDN) ligands has been demonstrated to exhibit antitumor activity through promotion of the activation of CD8+ T, natural killer, and dendritic cells in relevant tissues, meanwhile facilitating the antigen cross‐priming process during the immune responses.[30] Accompanied by the SDT modality, such agonist is believed to generate prominent sonoimmuno‐therapeutic consequences against malignant tumors with high efficiency.